Cengiz Müjgan, Ozaydin Ahmet, Ozkilic Anil Cagla, Dedekarginoglu Galip
Department Of Medical Biology, Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey.
Int Urol Nephrol. 2007;39(4):1043-8. doi: 10.1007/s11255-007-9179-9. Epub 2007 Mar 6.
Glutathione S transferases (GSTT1, GSTM1, GSTP1) are enzymes that activate the detoxification of endogenous and exogenous agents. The genetic polymorphism in these genes may change the response of individuals to environmental toxicants. The genetic polymorphisms of GSTT1, GSTM1, GSTP1 have been studied extensively in the determination of individual cancer risks. Some studies showed a strong relationship between polymorphism of GSTs and superoxidedismutase enzymes. Using the polymerase chain reaction (PCR) the prevalence of genetic polymorphisms of GSTT1, GSTM1 and MnSOD (Manganese Superoxide Dismurase) was investigated in 104 cases and controls to seek any association with the risk of bladder cancer. The frequency of GSTT1 +/+ polymorphism was 65% (33/51) in the cases and 79% (42/53) in the controls. The frequency of the GSTM1 +/+ polymorphism was 33% (17/51) in the cases and 58% (31/53) in the controls. The frequency of the GSTM1 null genotype was 42% (22/53) in the controls and 68% (34/51) in the patients. The frequency of the SOD AA genotype was 36% (17/51) in the cases and 33% (19/53) in the controls. There was no association between the GSTT1 and SOD polymorphism and bladder cancer incidence. The incidence of the GSTM1 null genotype was increased in bladder cancer patients compared to controls (OR = 1.755, 95% CI = 1.119-2.751).
谷胱甘肽S转移酶(GSTT1、GSTM1、GSTP1)是激活内源性和外源性物质解毒作用的酶。这些基因中的遗传多态性可能会改变个体对环境毒物的反应。GSTT1、GSTM1、GSTP1的遗传多态性在个体癌症风险的测定中已得到广泛研究。一些研究表明GSTs多态性与超氧化物歧化酶之间存在密切关系。使用聚合酶链反应(PCR)对104例病例和对照进行研究,以调查GSTT1、GSTM1和锰超氧化物歧化酶(MnSOD)的遗传多态性患病率,寻找与膀胱癌风险的任何关联。GSTT1 +/+多态性的频率在病例组中为65%(33/51),在对照组中为79%(42/53)。GSTM1 +/+多态性的频率在病例组中为33%(17/51),在对照组中为58%(31/53)。GSTM1无效基因型的频率在对照组中为42%(22/53),在患者组中为68%(34/51)。SOD AA基因型的频率在病例组中为36%(17/51),在对照组中为33%(19/53)。GSTT1和SOD多态性与膀胱癌发病率之间无关联。与对照组相比,膀胱癌患者中GSTM1无效基因型的发病率增加(OR = 1.755,95% CI = 1.119 - 2.751)。